Microbot Med Inc Stock Price, News & Analysis

Microbot Medical (Nasdaq: MBOT) announced a U.S.-based third-party logistics partnership to support commercialization of the FDA-cleared LIBERTY Endovascular Robotic System.

The company expects a limited market release in Q4 2025 and a broader commercial launch in April 2026 during the Society of Interventional Radiology conference. The 3PL partner offers integrated fulfillment, proximity to key markets, effective order processing, inventory maintenance, and a strategically located climate-controlled warehouse to meet expected demand.

Microbot Medical (Nasdaq: MBOT) completed the third and final closing of exercises of outstanding preferred investment options, issuing a total of 13,989,115 shares of common stock and raising approximately $29.2 million in gross proceeds across three closings ($25.2M, $1.2M, $2.8M) prior to fees.

The company issued new unregistered short-term Series J preferred investment options to purchase up to the same 13,989,115 shares with an $4.50 exercise price, exercisable beginning six months after issuance for a two-year term, representing potential additional gross proceeds of approximately $63 million if fully exercised. H.C. Wainwright acted as placement agent. Net proceeds are intended for LIBERTY robotic system development, regulatory and commercialization activities, potential acquisitions, IP applications, and working capital.

Microbot Medical (NASDAQ:MBOT) has secured its first patent in Japan for its LIBERTY® Endovascular Robotic System, strengthening its global intellectual property portfolio. The patent covers core technology including a compact robotic device for driving and manipulating elongate surgical tools.

The company has recently obtained patents in the U.S., China, and Israel over the past 90 days. Following FDA clearance on September 8, 2025, Microbot Medical is accelerating commercial launch plans, targeting an estimated 2.5 million annual peripheral endovascular procedures in the U.S. market.

Microbot Medical (NASDAQ:MBOT) announces that CEO Harel Gadot will participate in a livestream interview on Benzinga All Access on September 24, 2025, at 10:45am ET. The discussion will focus on the company's recent FDA 510(k) clearance for the LIBERTY® Endovascular Robotic System, which was received on September 8, 2025.

During the interview, Mr. Gadot will outline the company's commercialization strategy for LIBERTY® in the U.S. market and discuss how this innovative system aims to transform the peripheral endovascular space.

Microbot Medical (Nasdaq: MBOT) announced the first closing of its preferred investment options exercise, which could generate up to $92.2 million in total gross proceeds. The transaction includes $25.2 million from the first closing and expected $4 million from the second closing, with potential additional proceeds of $63 million if new short-term series J preferred investment options are fully exercised.

The first closing involves 12,064,627 shares at exercise prices of $1.50-$2.13 per share, while the second closing will include 1,924,488 shares at $2.10 per share. New series J options will have a $4.50 exercise price. Proceeds will fund the LIBERTY® Robotic System development, potential acquisitions, and working capital.

Microbot Medical (NASDAQ: MBOT) has announced significant preferred investment options exercise agreements that could generate up to $92.2 million in gross proceeds. The transaction will occur in two closings: a first closing of $25.2 million expected around September 16, 2025, and a second closing of $4 million by October 15, 2025.

The deal involves issuing new unregistered short-term series J preferred investment options to purchase up to 13,989,115 shares of common stock. These new options will have an exercise price of $4.50 per share, becoming exercisable six months after issuance with a two-year term, potentially generating an additional $63 million if fully exercised.

The company plans to use the proceeds for the development and commercialization of its LIBERTY® Robotic System, potential acquisitions, expansion of IP applications, and working capital.

Microbot Medical (NASDAQ:MBOT) announced that CEO Harel Gadot will present at the H.C. Wainwright Annual Investor Conference, focusing on the company's recent FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System. The LIBERTY® System is notable as the first single-use, remotely operated robotic system designed for peripheral endovascular procedures.

The presentation is scheduled for September 9th at 9:00am ET and will be available via webcast through the company's website.

Microbot Medical (Nasdaq: MBOT) has achieved a significant milestone with FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System, the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. The company plans to commence commercialization in Q4 2025, targeting an initial U.S. market of approximately 2.5 million annual peripheral vascular procedures.

The LIBERTY® pivotal study demonstrated remarkable results, including 100% success in robotic navigation to target, zero device-related adverse events, and a 92% reduction in physician radiation exposure. The system's remote design aims to improve ergonomics and reduce physical strain on healthcare providers while enhancing procedure efficiency and lowering costs.

Microbot Medical (Nasdaq: MBOT) has secured a significant new U.S. patent for its LIBERTY® Endovascular Robotic System, expanding its potential market applications. The patent covers a modular robotic surgical system with interchangeable tool-receiver units, strengthening the company's IP portfolio which now includes 12 granted patents globally and 57 pending applications.

This development could enable LIBERTY® to expand beyond its initial focus on peripheral endovascular procedures (estimated at 2.5 million annual procedures in the U.S.) to potentially reach over 6 million annual endovascular procedures. The company is currently awaiting FDA 510(k) clearance for LIBERTY®, which is notable for being the first fully disposable robotic system in its field.